NEURINOX aims at identifying novel therapeutic targets for neuroinflammatory diseases, by focusing on NADPH oxidases (NOX). NOX enzymes catalyse the formation of reactive oxygen species (ROS) and are key regulators of neuroinflammation. Establishment of chronic neuroinflammation is characterised by either increased or decreased NOX activity. The NEURINOX project aims at elucidating the links between neuroinflammation, NOX enzyme activity and neurodegenerative diseases (ND). It aims at validating NOX as therapeutic targets using animal models of neuroinflammation, human samples, prospective clinical studies and, in case of success of preclinical evaluation of NOX inhibitors in models of amyotrophic lateral sclerosis (ALS), an early clinical trial with ALS patients.
With a total budget of 15.4 M€ and a funding support of 11.4 M€ for 5 years from the European Union's Seventh Framework Programme (FP7) for Research and Technology Development, NEURINOX is coordinated by University of Geneva and includes several SMEs, internationally renowned research groups and clinical institutions with extensive experience in NOX research and neurodegenerative diseases.
As the project is ending on 31 December 2016, the Project consortium has hence issued a Position Paper giving an overview of what has been achieved in NEURINOX and the fields where we need a continued research effort to bring the NEURINOX findings closer to clinical application.
Discover the English version of the NEURINOX Graphic Novel ending with a lecture given by the scientist to high school students.
Now in French : Sans Crier Gare